ClinicalTrials.gg
TerminatedNCT03801525ULTRA-VUpdated Apr 19, 2024Results posted

Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)

A Phase 2/3 interventional study of Ublituximab and Umbralisib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by TG Therapeutics, Inc.. Terminated at 50 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-19.

Sponsored by TG Therapeutics, Inc. · Phase 2/3, Interventional, and Treatment

Why this study was terminated
Strategic/Business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
277
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell — none open to participants now, 1 under way, none of them phase 3. ublituximab · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
2nd of 13
277 · median 51
Started
2019
with 1 other
Phase 2/3
Only one
of the 13
Registered
10th of 13
by date
Lead sponsor
10 of 13
TG Therapeutics, Inc.

Among the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 2nd largest by enrollment, is one of 2 that started in 2019, is the only one in phase 2/3, and was the 10th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

None of the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell is open now. The open studies under Leukemia, Lymphocytic, Chronic, B-Cell, anywhere →

About ublituximab

ublituximab: first FDA approval 2022 (BRIUMVI), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell as a file.
02

Study summary

ULTRA-V: Study to Assess the Efficacy and Safety of Ublituximab in Combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects with Chronic Lymphocytic Leukemia (CLL)

Read the detailed description

This is an open-label, multicenter, Phase 2/3 study to evaluate the efficacy and safety of the combination of ublituximab + umbralisib + venetoclax (U2-V) compared to the combination of ublituximab + umbralisib (U2) in participants with either treatment naïve or previously treated CLL/ small lymphocytic lymphoma (SLL).

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Keywords

  • CLL
  • SLL
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL) that warrants treatment
  • Adequate organ system function as specified in the protocol
  • Ability to follow protocol procedures.

Exclusion criteria

Exclusion Criteria:

  • Subjects receiving cancer therapy or any drug within 21 days of Cycle 1, Day 1
  • Prior exposure to any PI3K inhibitor or venetoclax
  • Autologous hematologic stem cell transplant within 6 months of study entry. Prior allogeneic hematologic stem cell transplant is excluded
  • Active or .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
277 participants (actual)

Study arms

  • Experimental
    Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V)

    Participants were administered ublituximab, 150 milligrams (mg), intravenous (IV) infusion on Day 1, 750 mg on Day 2, 900 mg on Days 8 and 15 of Cycle 1, followed by 900 mg on Day 1 of Cycles 2-6; umbralisib, 800 mg, oral tablet, once daily (QD) through Cycles 1-24; venetoclax, oral tablet, QD, 20 mg on Days 1-7, 50 mg on Days 8-14, 100 mg on Days 15-21, 200 mg on Days 22-28 of Cycle 4, followed by 400 mg on Days 1-28 of Cycles 5-24. MRD positive participants were administered umbralisib, 800 mg, oral tablet, QD, on Days 1-28 from Cycle 25 onwards (1 Cycle = 28 days), until disease progression, unacceptable toxicity, or withdrawal from the study.

    Drug: Ublituximab · Drug: Umbralisib · Drug: Venetoclax

  • Experimental
    Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V)

    Participants were administered ublituximab, 150 mg, IV infusion on Day 1, 750 mg on Day 2, 900 mg on Days 8 and 15 of Cycle 1, followed by 900 mg on Day 1 of Cycles 2-6, 9,12, and 15; umbralisib, 800 mg, oral tablet, QD through Cycles 1-15; venetoclax, oral tablet, QD, 20 mg on Days 1-7, 50 mg on Days 8-14, 100 mg on Days 15-21, 200 mg on Days 22-28 of Cycle 4, followed by 400 mg on Days 1-28 of Cycles 5-15 (1 Cycle = 28 days).

    Drug: Ublituximab · Drug: Umbralisib · Drug: Venetoclax

  • Experimental
    Phase 3: Ublituximab + Umbralisib (U2)

    Participants were administered ublituximab, 150 mg, IV infusion on Day 1, 750 mg on Day 2, 900 mg on Days 8 and 15 of Cycle 1, followed by 900 mg on Day 1 of Cycles 2-6, then every three cycles along with umbralisib, 800 mg, oral tablet, QD (1 Cycle = 28 days) from Cycle 1 until disease progression, unacceptable toxicity, or withdrawal from the study.

    Drug: Ublituximab · Drug: Umbralisib

Interventions

  • * recombinant chimeric anti-CD20 (cluster of differentiation 20) monoclonal antibody * administered as an IV infusion

    Also known as: TG-1101

  • * inhibitor of phosphoinositide 3-kinase (PI3K) delta and casein kinase 1 epsilon (CK1e) * Tablet form

    Also known as: TGR-1202, UKONIQ

  • * B-cell lymphoma 2 (BCL-2) inhibitor * Tablet form

    Also known as: Venclexta®

06

What researchers measure

Primary outcomes

  1. Phase 2: Complete Response (CR) Rate as Per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 Criteria

    CR rate=percent of participants who achieved CR or complete response with incomplete marrow recovery(CRi).CR=no evidence of new disease,absolute lymphocyte count(ALC) in peripheral blood\<4x10\^9 per liter(/L),regression of nodal masses to normal size \<1.5 centimeters(cm) in longest diameter(LD),normal spleen and liver size,no constitutional symptoms,cytological/pathological evaluation of bone marrow(BM) smear/biopsy must be at least normocellular for age without evidence for typical chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma(SLL) lymphocytes by morphological criteria,peripheral blood counts with absolute neutrophil count(ANC)≥1.5x10\^9/L or platelet≥100x10\^9/L or hemoglobin≥110 grams per liter(g/L) without red blood cell(RBC) transfusions,all without need for exogenous growth factors.CRi=all CR criteria but with persistent anemia,thrombocytopenia,or neutropenia or hypocellular BM that is related to prior/ongoing drug toxicity(and not to CLL/SLL).

    Time frame: Up to 43.2 months

  2. Phase 2: Overall Response Rate (ORR) Per iwCLL 2018 Criteria

    ORR=percent of participants who achieve CR,CRi,partial response(PR) or PR with lymphocytosis(PR-L).CR=no evidence of new disease;ALC\<4x10\^9/L;regression of nodal masses to\<1.5cm LD;normal spleen,liver size;no constitutional symptoms;cytological/pathological evaluation of BM smear/biopsy must be at least normocellular for age;ANC≥1.5x10\^9/L,platelet≥100x10\^9/L,Hb≥110g/L.CRi=CR criteria but with persistent anemia,thrombocytopenia,or neutropenia/hypocellular BM related to prior/ongoing drug toxicity.PR=no evidence of new disease,meets≥2 criteria:≥50% decrease from baseline(BL) in ALC(or decrease to\<4x10\^9/L) or sum of products(SPD) of target nodal lesions or CLL/SLL marrow infiltrate/Blymphoid;no target,splenic,liver,or non-target disease with worsening that meets criteria for definitive progressive disease(PD);platelet\>100x10\^9/L or Hb≥110g/L or ≥50% increase from BL in each.PR-L=PR criteria but not had ≥50% decrease from BL in ALC/decrease to\<4x10\^9/L.

    Time frame: Up to 43.2 months

  3. Phase 3: Progression-Free Survival (PFS) Per iwCLL 2018 Criteria

    PFS was assessed in participants treated with U2-V compared with U2. PFS was defined as the interval between randomization and the date of definitive PD (as confirmed by the IRC) or death due to any cause, whichever occurs first. Participants who had no event (progression or death) were censored at the day of their last adequate disease assessment. PD= appearance of new nodes \>1.5 cm in the LD, \>50% increase in greatest diameter, new or recurrent hepatomegaly or splenomegaly, new unequivocal extra-nodal lesion, new non-target disease, ≥50% increase from the nadir in the sum of products of diameters (SPD) of target lesions, ≥50% increase in the LD of an individual node or extra-nodal mass, splenic/hepatic enlargement of ≥50% from nadir, unequivocal increase in the size of non-target disease, transformation to a more aggressive histology, decrease in platelet count or Hgb, \>50% decrease from the highest on-study platelet count, \>20 g/L decrease from the highest on-study Hgb.

    Time frame: Up to 43.2 months

Secondary outcomes

  1. Minimal Residual Disease (MRD) Negativity Rate

    The MRD negativity rate was defined as the percentage of participants who achieved MRD negative status post-baseline, defined as a quantitative detection of less than one CLL/SLL cell in 10000 leukocytes by flow cytometry (MRD level, 10\^-4) in blood or bone marrow (BM). If a participant was determined to be MRD negative by peripheral blood, a bone marrow aspirate was obtained to assess MRD in the bone marrow. Participants who did not have an MRD assessment at any post-baseline visits were considered non-responders and were included in the denominator when calculating MRD negativity rate.

    Time frame: Up to 43.2 months

  2. Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)

    An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product. An AE does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is any AE that occur after first dosing of study medication and through the end of the study or through 30 days after the last dose of study treatment, or is considered treatment-related regardless of the start date of the event, or is present before first dosing of study medication but worsens in intensity or the investigator subsequently considers treatment-related.

    Time frame: Up to 43.2 months

  3. Phase 2: Time to Response (TTR) Per iwCLL 2018 Criteria

    TTR was defined as the interval from enrollment to first documentation of CR, CRi, PR, or PR-L. TTR was analyzed via Kaplan-Meier method. CR=no evidence of new disease; ALC\<4x10\^9/L; regression of nodal masses to \<1.5cm LD; normal spleen ,liver size; no constitutional symptoms; cytological/pathological evaluation of BM smear/biopsy must be at least normocellular for age; ANC≥1.5x10\^9/L, platelet≥100x10\^9/L, Hb≥110g/L. CRi=CR criteria but with persistent anemia, thrombocytopenia, or neutropenia/hypocellular BM related to prior/ongoing drug toxicity.PR=no evidence of new disease,meets≥2 criteria:≥50% decrease from BL in ALC (or decrease to\<4x10\^9/L) or SPD of target nodal lesions or CLL/SLL marrow infiltrate/B-lymphoid; no target, splenic, liver, or non-target disease with worsening that meets criteria for definitive PD; platelet\>100x10\^9/L or Hb≥110g/L or ≥50% increase from BL in each.PR-L=PR criteria but not had ≥50% decrease from BL in ALC/decrease to\<4x10\^9/L.

    Time frame: Up to 43.2 months

  4. Phase 2: Duration of Response (DOR) Per iwCLL 2018 Criteria

    DOR=interval from 1st documentation of CR,CRi,PR or PR-L to earlier of 1st documentation of definitive PD or death from any cause.CR=no evidence of new disease;ALC\<4x10\^9/L;regression of nodal masses to\<1.5cm LD;normal spleen,liver size;no constitutional symptoms;cytological/pathological evaluation of BM smear/biopsy must be at least normocellular for age;ANC≥1.5x10\^9/L,platelet≥100x10\^9/L,Hb≥110g/L.CRi=CR criteria but with persistent anemia,thrombocytopenia,neutropenia/hypocellular BM related to prior/ongoing drug toxicity.PR=no evidence of new disease,meets≥2 criteria:≥50% decrease from BL in ALC(or decrease to\<4x10\^9/L) or SPD of target nodal lesions or CLL/SLL marrow infiltrate/Blymphoid;no target,splenic,liver,or non-target disease with worsening that meets criteria for definitive PD;platelet\>100x10\^9/L or Hb≥110g/L or ≥50% increase from BL in each.PR-L=PR criteria;not≥50% decrease from BL in ALC/decrease to\<4x10\^9/L.PD=evidence of new disease per protocol-specififed criteria.

    Time frame: Up to 43.2 months

  5. Phase 3: CR Rate as Assessed by an Independent Review Committee (IRC) Per iwCLL 2018 Criteria

    CR rate=percent of participants who achieved CR or CRi. CR=no evidence of new disease; ALC\<4x10\^9/L; regression of nodal masses to \<1.5 cm LD; normal spleen, liver size; no constitutional symptoms; cytological/pathological evaluation of BM smear/biopsy must be at least normocellular for age; ANC ≥1.5x10\^9/L, platelet ≥100x10\^9/L, Hb ≥110g/L. CRi=CR criteria but with persistent anemia,thrombocytopenia,or neutropenia/hypocellular BM related to prior/ongoing drug toxicity. CR assessment was subject to independent confirmation by the IRC in participants enrolled to the Phase 3 stage of the study.

    Time frame: Up to 43.2 months

  6. Phase 3: ORR as Assessed by IRC Per iwCLL 2018 Criteria

    ORR=percent of participants who achieve CR, CRi, PR or PR-L.CR=no evidence of new disease; ALC\<4x10\^9/L; regression of nodal masses to\<1.5cm LD; normal spleen and liver size; no constitutional symptoms; cytological/pathological evaluation of BM smear/biopsy must be at least normocellular for age; ANC≥1.5x10\^9/L, platelet≥100x10\^9/L, Hb≥110g/L. CRi=CR criteria but with persistent anemia, thrombocytopenia, or neutropenia/hypocellular BM related to prior/ongoing drug toxicity.PR=no evidence of new disease,meets≥2 criteria:≥50% decrease from baseline (BL) in ALC (or decrease to\<4x10\^9/L) or SPD of target nodal lesions or CLL/SLL marrow infiltrate/B-lymphoid; no target, splenic, liver, or non-target disease with worsening that meets criteria for definitive PD; platelet\>100x10\^9/L or Hb≥110g/L or ≥50% increase from BL in each.PR-L=PR criteria but not had ≥50% decrease from BL in ALC/decrease to\<4x10\^9/L.

    Time frame: Up to 43.2 months

  7. Phase 3: Overall Survival (OS)

    Overall Survival (OS) was defined as the interval from randomization to death from any cause. OS data was censored at the last documented date that the participant was confirmed alive for participants who withdrew consent or were lost to follow-up prior to the end of the study, and for participants whose vital status in the study could not be determined.

    Time frame: Up to 43.2 months

07

Results

Posted Apr 19, 2024
Limitations and caveats
Due to sponsor's business decision, the clinical trial was terminated by the sponsor prematurely. As such, the study results are reflective of the data captured to the time of study termination and with limited data verification.

Participant flow

A total of 277 participants were enrolled at investigative sites in the United States from 16 May 2019 to 20 December 2022.

Participant flow — Overall Study
MilestonePhase 2: Ublituximab + Umbralisib + Venetoclax (U2-V)Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V)Phase 3: Ublituximab + Umbralisib (U2)
Started1655656
Intent-to-treat (itt) population1495656
Completed1100
Not completed1545656
Withdrew: Adverse event1710
Withdrew: Conditions requiring therapeutic intervention not permitted by the protocol100
Withdrew: Death2914
Withdrew: Disease progression601
Withdrew: Inability to comply with study requirements110
Withdrew: Investigator decision1810
Withdrew: Minimal residual disease (mrd) negativity and tumor response1400
Withdrew: Sponsor discontinuation of the study244943
Withdrew: Started non-protocol anti-cancer therapy213
Withdrew: Withdrawal of subject consent3821
Withdrew: Reason not specified404

Outcome measures

PrimaryPhase 2: Complete Response (CR) Rate as Per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 Criteria

CR rate=percent of participants who achieved CR or complete response with incomplete marrow recovery(CRi).CR=no evidence of new disease,absolute lymphocyte count(ALC) in peripheral blood\<4x10\^9 per liter(/L),regression of nodal masses to normal size \<1.5 centimeters(cm) in longest diameter(LD),normal spleen and liver size,no constitutional symptoms,cytological/pathological evaluation of bone marrow(BM) smear/biopsy must be at least normocellular for age without evidence for typical chronic lymphocytic leukemia(CLL)/small lymphocytic lymphoma(SLL) lymphocytes by morphological criteria,peripheral blood counts with absolute neutrophil count(ANC)≥1.5x10\^9/L or platelet≥100x10\^9/L or hemoglobin≥110 grams per liter(g/L) without red blood cell(RBC) transfusions,all without need for exogenous growth factors.CRi=all CR criteria but with persistent anemia,thrombocytopenia,or neutropenia or hypocellular BM that is related to prior/ongoing drug toxicity(and not to CLL/SLL).

Time frame:
Up to 43.2 months
Reported as:
Number · percentage of participants
Phase 2: Complete Response (CR) Rate as Per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 Criteria
percentage of participantsPhase 2: Ublituximab + Umbralisib + Venetoclax (U2-V)
Phase 2: Complete Response (CR) Rate as Per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 Criteria33.6
PrimaryPhase 2: Overall Response Rate (ORR) Per iwCLL 2018 Criteria

ORR=percent of participants who achieve CR,CRi,partial response(PR) or PR with lymphocytosis(PR-L).CR=no evidence of new disease;ALC\<4x10\^9/L;regression of nodal masses to\<1.5cm LD;normal spleen,liver size;no constitutional symptoms;cytological/pathological evaluation of BM smear/biopsy must be at least normocellular for age;ANC≥1.5x10\^9/L,platelet≥100x10\^9/L,Hb≥110g/L.CRi=CR criteria but with persistent anemia,thrombocytopenia,or neutropenia/hypocellular BM related to prior/ongoing drug toxicity.PR=no evidence of new disease,meets≥2 criteria:≥50% decrease from baseline(BL) in ALC(or decrease to\<4x10\^9/L) or sum of products(SPD) of target nodal lesions or CLL/SLL marrow infiltrate/Blymphoid;no target,splenic,liver,or non-target disease with worsening that meets criteria for definitive progressive disease(PD);platelet\>100x10\^9/L or Hb≥110g/L or ≥50% increase from BL in each.PR-L=PR criteria but not had ≥50% decrease from BL in ALC/decrease to\<4x10\^9/L.

Time frame:
Up to 43.2 months
Reported as:
Number · percentage of participants
Phase 2: Overall Response Rate (ORR) Per iwCLL 2018 Criteria
percentage of participantsPhase 2: Ublituximab + Umbralisib + Venetoclax (U2-V)
Phase 2: Overall Response Rate (ORR) Per iwCLL 2018 Criteria93.3
PrimaryPhase 3: Progression-Free Survival (PFS) Per iwCLL 2018 Criteria

PFS was assessed in participants treated with U2-V compared with U2. PFS was defined as the interval between randomization and the date of definitive PD (as confirmed by the IRC) or death due to any cause, whichever occurs first. Participants who had no event (progression or death) were censored at the day of their last adequate disease assessment. PD= appearance of new nodes \>1.5 cm in the LD, \>50% increase in greatest diameter, new or recurrent hepatomegaly or splenomegaly, new unequivocal extra-nodal lesion, new non-target disease, ≥50% increase from the nadir in the sum of products of diameters (SPD) of target lesions, ≥50% increase in the LD of an individual node or extra-nodal mass, splenic/hepatic enlargement of ≥50% from nadir, unequivocal increase in the size of non-target disease, transformation to a more aggressive histology, decrease in platelet count or Hgb, \>50% decrease from the highest on-study platelet count, \>20 g/L decrease from the highest on-study Hgb.

Time frame:
Up to 43.2 months
Reported as:
Median · months
Phase 3: Progression-Free Survival (PFS) Per iwCLL 2018 Criteria
monthsPhase 3: Ublituximab + Umbralisib + Venetoclax (U2-V)Phase 3: Ublituximab + Umbralisib (U2)
Phase 3: Progression-Free Survival (PFS) Per iwCLL 2018 CriteriaNA (0.0 to 15.7)NA (0.0 to 13.1)
Statistical analysis
  • Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V) vs Phase 3: Ublituximab + Umbralisib (U2) · Log Rank · p = 0.6960 · Hazard ratio (hr): 0.778 · 95% CI 0.219 to 2.755
SecondaryMinimal Residual Disease (MRD) Negativity Rate

The MRD negativity rate was defined as the percentage of participants who achieved MRD negative status post-baseline, defined as a quantitative detection of less than one CLL/SLL cell in 10000 leukocytes by flow cytometry (MRD level, 10\^-4) in blood or bone marrow (BM). If a participant was determined to be MRD negative by peripheral blood, a bone marrow aspirate was obtained to assess MRD in the bone marrow. Participants who did not have an MRD assessment at any post-baseline visits were considered non-responders and were included in the denominator when calculating MRD negativity rate.

Time frame:
Up to 43.2 months
Reported as:
Number · percentage of participants
Minimal Residual Disease (MRD) Negativity Rate
percentage of participantsPhase 2: Ublituximab + Umbralisib + Venetoclax (U2-V)Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V)Phase 3: Ublituximab + Umbralisib (U2)
Minimal Residual Disease (MRD) Negativity Rate94.0 (88.8 to 97.2)50.0 (36.3 to 63.7)19.6 (10.2 to 32.4)
SecondaryNumber of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)

An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product. An AE does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is any AE that occur after first dosing of study medication and through the end of the study or through 30 days after the last dose of study treatment, or is considered treatment-related regardless of the start date of the event, or is present before first dosing of study medication but worsens in intensity or the investigator subsequently considers treatment-related.

Time frame:
Up to 43.2 months
Reported as:
Count of participants · Participants
Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)
ParticipantsPhase 2: Ublituximab + Umbralisib + Venetoclax (U2-V)Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V)Phase 3: Ublituximab + Umbralisib (U2)
Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)1655651
SecondaryPhase 2: Time to Response (TTR) Per iwCLL 2018 Criteria

TTR was defined as the interval from enrollment to first documentation of CR, CRi, PR, or PR-L. TTR was analyzed via Kaplan-Meier method. CR=no evidence of new disease; ALC\<4x10\^9/L; regression of nodal masses to \<1.5cm LD; normal spleen ,liver size; no constitutional symptoms; cytological/pathological evaluation of BM smear/biopsy must be at least normocellular for age; ANC≥1.5x10\^9/L, platelet≥100x10\^9/L, Hb≥110g/L. CRi=CR criteria but with persistent anemia, thrombocytopenia, or neutropenia/hypocellular BM related to prior/ongoing drug toxicity.PR=no evidence of new disease,meets≥2 criteria:≥50% decrease from BL in ALC (or decrease to\<4x10\^9/L) or SPD of target nodal lesions or CLL/SLL marrow infiltrate/B-lymphoid; no target, splenic, liver, or non-target disease with worsening that meets criteria for definitive PD; platelet\>100x10\^9/L or Hb≥110g/L or ≥50% increase from BL in each.PR-L=PR criteria but not had ≥50% decrease from BL in ALC/decrease to\<4x10\^9/L.

Time frame:
Up to 43.2 months
Reported as:
Median · months
Phase 2: Time to Response (TTR) Per iwCLL 2018 Criteria
monthsPhase 2: Ublituximab + Umbralisib + Venetoclax (U2-V)
Phase 2: Time to Response (TTR) Per iwCLL 2018 Criteria2.6 (2.3 to 18.5)
SecondaryPhase 2: Duration of Response (DOR) Per iwCLL 2018 Criteria

DOR=interval from 1st documentation of CR,CRi,PR or PR-L to earlier of 1st documentation of definitive PD or death from any cause.CR=no evidence of new disease;ALC\<4x10\^9/L;regression of nodal masses to\<1.5cm LD;normal spleen,liver size;no constitutional symptoms;cytological/pathological evaluation of BM smear/biopsy must be at least normocellular for age;ANC≥1.5x10\^9/L,platelet≥100x10\^9/L,Hb≥110g/L.CRi=CR criteria but with persistent anemia,thrombocytopenia,neutropenia/hypocellular BM related to prior/ongoing drug toxicity.PR=no evidence of new disease,meets≥2 criteria:≥50% decrease from BL in ALC(or decrease to\<4x10\^9/L) or SPD of target nodal lesions or CLL/SLL marrow infiltrate/Blymphoid;no target,splenic,liver,or non-target disease with worsening that meets criteria for definitive PD;platelet\>100x10\^9/L or Hb≥110g/L or ≥50% increase from BL in each.PR-L=PR criteria;not≥50% decrease from BL in ALC/decrease to\<4x10\^9/L.PD=evidence of new disease per protocol-specififed criteria.

Time frame:
Up to 43.2 months
Reported as:
Median · months
Phase 2: Duration of Response (DOR) Per iwCLL 2018 Criteria
monthsPhase 2: Ublituximab + Umbralisib + Venetoclax (U2-V)
Phase 2: Duration of Response (DOR) Per iwCLL 2018 Criteria21.1 (0.0 to 24.8)
SecondaryPhase 3: CR Rate as Assessed by an Independent Review Committee (IRC) Per iwCLL 2018 Criteria

CR rate=percent of participants who achieved CR or CRi. CR=no evidence of new disease; ALC\<4x10\^9/L; regression of nodal masses to \<1.5 cm LD; normal spleen, liver size; no constitutional symptoms; cytological/pathological evaluation of BM smear/biopsy must be at least normocellular for age; ANC ≥1.5x10\^9/L, platelet ≥100x10\^9/L, Hb ≥110g/L. CRi=CR criteria but with persistent anemia,thrombocytopenia,or neutropenia/hypocellular BM related to prior/ongoing drug toxicity. CR assessment was subject to independent confirmation by the IRC in participants enrolled to the Phase 3 stage of the study.

Time frame:
Up to 43.2 months
Reported as:
Number · percentage of participants
Phase 3: CR Rate as Assessed by an Independent Review Committee (IRC) Per iwCLL 2018 Criteria
percentage of participantsPhase 3: Ublituximab + Umbralisib + Venetoclax (U2-V)Phase 3: Ublituximab + Umbralisib (U2)
Phase 3: CR Rate as Assessed by an Independent Review Committee (IRC) Per iwCLL 2018 Criteria17.98.9
SecondaryPhase 3: ORR as Assessed by IRC Per iwCLL 2018 Criteria

ORR=percent of participants who achieve CR, CRi, PR or PR-L.CR=no evidence of new disease; ALC\<4x10\^9/L; regression of nodal masses to\<1.5cm LD; normal spleen and liver size; no constitutional symptoms; cytological/pathological evaluation of BM smear/biopsy must be at least normocellular for age; ANC≥1.5x10\^9/L, platelet≥100x10\^9/L, Hb≥110g/L. CRi=CR criteria but with persistent anemia, thrombocytopenia, or neutropenia/hypocellular BM related to prior/ongoing drug toxicity.PR=no evidence of new disease,meets≥2 criteria:≥50% decrease from baseline (BL) in ALC (or decrease to\<4x10\^9/L) or SPD of target nodal lesions or CLL/SLL marrow infiltrate/B-lymphoid; no target, splenic, liver, or non-target disease with worsening that meets criteria for definitive PD; platelet\>100x10\^9/L or Hb≥110g/L or ≥50% increase from BL in each.PR-L=PR criteria but not had ≥50% decrease from BL in ALC/decrease to\<4x10\^9/L.

Time frame:
Up to 43.2 months
Reported as:
Number · percentage of participants
Phase 3: ORR as Assessed by IRC Per iwCLL 2018 Criteria
percentage of participantsPhase 3: Ublituximab + Umbralisib + Venetoclax (U2-V)Phase 3: Ublituximab + Umbralisib (U2)
Phase 3: ORR as Assessed by IRC Per iwCLL 2018 Criteria71.462.5
SecondaryPhase 3: Overall Survival (OS)

Overall Survival (OS) was defined as the interval from randomization to death from any cause. OS data was censored at the last documented date that the participant was confirmed alive for participants who withdrew consent or were lost to follow-up prior to the end of the study, and for participants whose vital status in the study could not be determined.

Time frame:
Up to 43.2 months
Reported as:
Median · months
Phase 3: Overall Survival (OS)
monthsPhase 3: Ublituximab + Umbralisib + Venetoclax (U2-V)Phase 3: Ublituximab + Umbralisib (U2)
Phase 3: Overall Survival (OS)NA (0.5 to 16.6)NA (0.0 to 16.2)
Statistical analysis
  • Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V) vs Phase 3: Ublituximab + Umbralisib (U2) · Log Rank · p = 0.1038 · Hazard ratio (hr): 0.201 · 95% CI 0.023 to 1.721

Adverse events

Collected over Up to 43.2 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V)32/165 (19.4%)84/165 (50.9%)165/165 (100%)
Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V)1/56 (1.8%)12/56 (21.4%)56/56 (100%)
Phase 3: Ublituximab + Umbralisib (U2)5/56 (8.9%)16/53 (30.2%)49/53 (92.5%)
Most frequent serious events
Showing 10 of 87
Most frequent serious events
EventPhase 2: Ublituximab + Umbralisib + Venetoclax (U2-V)Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V)Phase 3: Ublituximab + Umbralisib (U2)
COVID-19Infections and infestations15/1650/563/53
COVID-19 pneumoniaInfections and infestations13/1652/564/53
PneumoniaInfections and infestations9/1652/562/53
ColitisGastrointestinal disorders7/1650/560/53
Infusion related reactionInjury, poisoning and procedural complications2/1651/562/53
Blood bilirubin increasedInvestigations0/1650/562/53
Febrile neutropeniaBlood and lymphatic system disorders5/1652/560/53
Atrial fibrillationCardiac disorders5/1650/560/53
Acute kidney injuryRenal and urinary disorders5/1650/560/53
PyrexiaGeneral disorders3/1651/561/53
Most frequent other events
Showing 10 of 90
Most frequent other events
EventPhase 2: Ublituximab + Umbralisib + Venetoclax (U2-V)Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V)Phase 3: Ublituximab + Umbralisib (U2)
DiarrhoeaGastrointestinal disorders120/16530/5623/53
Infusion related reactionInjury, poisoning and procedural complications112/16538/5626/53
NauseaGastrointestinal disorders94/16526/5627/53
Neutrophil count decreasedInvestigations77/16520/5610/53
FatigueGeneral disorders74/16525/5617/53
Alanine aminotransferase increasedInvestigations31/16510/5617/53
InsomniaPsychiatric disorders47/16516/5612/53
Aspartate aminotransferase increasedInvestigations33/16512/5615/53
HeadacheNervous system disorders43/16515/5613/53
DizzinessNervous system disorders43/1659/569/53

Baseline characteristics

Safety population consisted of all participants who received at least one dose of any study drug (ublituximab, umbralisib, and venetoclax).

Age, Continuous
Age, Continuous(years)Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V)Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V)Phase 3: Ublituximab + Umbralisib (U2)Total
Mean65.9 (44 to 85)65.5 (46 to 91)62.9 (38 to 80)65.3 (38 to 91)
Sex: Female, Male
Sex: Female, Male(Participants)Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V)Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V)Phase 3: Ublituximab + Umbralisib (U2)Total
Female60221496
Male1053439178
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V)Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V)Phase 3: Ublituximab + Umbralisib (U2)Total
Hispanic or Latino5218
Not Hispanic or Latino1585349260
Unknown or Not Reported2136
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 2: Ublituximab + Umbralisib + Venetoclax (U2-V)Phase 3: Ublituximab + Umbralisib + Venetoclax (U2-V)Phase 3: Ublituximab + Umbralisib (U2)Total
Race — White/Caucasian1475144242
Race — Black or African American62412
Race — Asian2002
Race — American Indian or Alaska Native1001
Race — Hispanic1001
Race — Unknown83516
08

Study locations

50 sites
  • TG Therapeutics Investigational Trial Site
    Birmingham, Alabama 35294, United States
  • TG Therapeutics Investigational Trial Site
    Huntsville, Alabama 35805, United States
  • TG Therapeutics Investigational Trial Site
    Tucson, Arizona 85711, United States
  • TG Therapeutics Investigational Trial Site
    Duarte, California 91010, United States
  • TG Therapeutics Investigational Trial Site
    La Jolla, California 92093, United States
  • TG Therapeutics Investigational Trial Site
    Aurora, Colorado 80012, United States
  • TG Therapeutics Investigational Trial Site
    Stamford, Connecticut 06904, United States
  • TG Therapeutics Investigational Trial Site
    Boca Raton, Florida 33486, United States
  • TG Therapeutics Investigational Trial Site
    Fort Myers, Florida 33901, United States
  • TG Therapeutics Investigational Trial Site
    Jacksonville, Florida 32224, United States
  • TG Therapeutics Investigational Trial Site
    Saint Petersburg, Florida 33705, United States
  • TG Therapeutics Investigational Trial Site
    Tampa, Florida 33612, United States
  • TG Therapeutics Investigational Trial Site
    Atlanta, Georgia 30322, United States
  • TG Therapeutics Investigational Trial Site
    Decatur, Illinois 62526, United States
  • TG Therapeutics Investigational Trial Site
    Niles, Illinois 60714, United States
  • TG Therapeutics Investigational Site
    Peoria, Illinois 61615, United States
  • TG Therapeutics Investigational Trial Site
    Fort Wayne, Indiana 46804, United States
  • TG Therapeutics Investigational Trial Site
    Indianapolis, Indiana 46237, United States
  • TG Therapeutics Investigational Trial Site
    Des Moines, Iowa 50309, United States
  • TG Therapeutics Investigational Trial Site
    Westwood, Kansas 66210, United States
  • TG Therapeutics Investigational Site
    Louisville, Kentucky 40207, United States
  • TG Therapeutics Investigational Trial Site
    Bethesda, Maryland 37210, United States
  • TG Therapeutics Investigational Trial Site
    Columbia, Maryland 21044, United States
  • TG Therapeutics Investigational Trial Site
    Ann Arbor, Michigan 48197, United States
  • TG Therapeutics Investigational Trial Site
    Detroit, Michigan 48201, United States
  • TG Therapeutics Investigational Trial Site
    Detroit, Michigan 48202, United States
  • TG Therapeutics Investigational Trial Site
    Rochester, Minnesota 55905, United States
  • TG Therapeutics Investigational Trial Site
    Omaha, Nebraska 68198, United States
  • TG Therapeutics Investigational Trial Site
    Lebanon, New Hampshire 03756, United States
  • TG Therapeutics Investigational Trial Site
    Hackensack, New Jersey 07601, United States
  • TG Therapeutics Investigational Trial Site
    Morristown, New Jersey 07960, United States
  • TG Therapeutics Investigational Trial Site
    New York, New York 10065, United States
  • TG Therapeutics Investigational Trial Site
    Charlotte, North Carolina 28204, United States
  • TG Therapeutics Investigational Trial Site
    Columbus, Ohio 43210, United States
  • TG Therapeutics Investigational Trial Site
    Eugene, Oregon 97401, United States
  • TG Therapeutics Investigational Trial Site
    Philadelphia, Pennsylvania 19106, United States
  • TG Therapeutics Investigational Trial Site
    Charleston, South Carolina 29414, United States
  • TG Therapeutics Investigational Trial Site
    Greenville, South Carolina 29616, United States
  • TG Therapeutics Investigational Trial Site
    Chattanooga, Tennessee 37404, United States
  • TG Therapeutics Investigational Trial Site
    Knoxville, Tennessee 37916, United States
  • TG Therapeutics Investigational Trial Site
    Nashville, Tennessee 37203, United States
  • TG Therapeutics Investigational Trial Site
    Austin, Texas 78705, United States
  • TG Therapeutics Investigational Trial Site
    San Antonio, Texas 78229, United States
  • TG Therapeutics Investigational Trial Site
    Tyler, Texas 75702, United States
  • TG Therapeutics Investigational Trial Site
    Ogden, Utah 84405, United States
  • TG Therapeutics Investigational Trial Site
    Salt Lake City, Utah 84106, United States
  • TG Therapeutics Investigational Trial Site
    Blacksburg, Virginia 24060, United States
  • TG Therapeutics Investigational Trial Site
    Gainesville, Virginia 20155, United States
  • TG Therapeutics Investigational Trial Site
    Seattle, Washington 98104, United States
  • TG Therapeutics Investigational Trial Site
    Seattle, Washington 98108, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2019 to primary completion in Dec 2022, 43 months.

Results were first posted in Apr 2024, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2019
First posted
Jan 11, 2019
StartActual
May 16, 2019
Primary completionActual
Dec 20, 2022
CompletionActual
Dec 20, 2022
Results first posted
Apr 19, 2024
Last update
Apr 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03801525
Responsible party
Sponsor
First posted
Jan 11, 2019
Start date
May 16, 2019
Primary completion
Dec 20, 2022
Completion
Dec 20, 2022
Results posted
Apr 19, 2024
Last update
Apr 19, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ublituximab · Umbralisib

Start the discussion